GSK and Hengrui Pharma Announce $12 Billion Collaboration on Innovative Medicines
Hengrui Pharma and GSK have entered into agreements to develop up to 12 innovative medicines, including a potential best-in-class PDE3/4 inhibitor for COPD, with GSK paying $500 million upfront and the potential for up to $12 billion in milestone payments, enhancing their global pipeline and growth prospects.